Padua Prediction Score for Risk of VTE

Why use it

VTE is the leading cause of preventable hospital deaths worldwide, causing an estimated 300,000 deaths annually in the United States. Despite the availability of effective prophylaxis, medical patients are systematically underprophylaxed. The Padua score provides a standardized, evidence-based assessment that moves beyond clinical gestalt, ensuring consistent identification of high-risk patients who benefit from anticoagulant prophylaxis while avoiding unnecessary bleeding risk in low-risk patients.

About

The Padua Prediction Score (PPS) is a validated clinical risk assessment model developed by Barbar and colleagues at the University of Padua and published in the Journal of Thrombosis and Haemostasis in 2010. It was designed to identify hospitalized medical (non-surgical) patients at high risk for venous thromboembolism (VTE) — specifically deep vein thrombosis (DVT) and pulmonary embolism (PE) — who should receive pharmacological thromboprophylaxis during hospitalization. The score comprises 11 clinical factors, each weighted by its contribution to VTE risk, generating a total score of 0 to 20. Patients with a Padua score ≥4 are classified as high risk and should receive low molecular weight heparin (LMWH) or unfractionated heparin (UFH) thromboprophylaxis unless contraindicated. The score was derived in 1,180 consecutive medical inpatients and validated in a separate cohort. In high-risk patients (score ≥4) without prophylaxis, the 90-day VTE rate was 11.0% versus 0.3% in low-risk patients. The Padua score is recommended by the American College of Chest Physicians (CHEST) guidelines and the International Union of Angiology for VTE risk assessment in hospitalized medical patients.

When to use

• All hospitalized medical (non-surgical) patients at time of admission to determine VTE prophylaxis need
• Reassessment when clinical status changes (new immobility, worsening infection, escalating oxygen requirements)
• Before discharging recently hospitalized patients — consider extended prophylaxis for high-risk patients
• NOT validated for surgical patients (use Caprini Score for surgery), obstetric patients, or ICU patients
• NOT a substitute for bleeding risk assessment — always evaluate bleeding contraindications before initiating prophylaxis

Formula

Pearls & pitfalls

• Active cancer is the highest-weighted single risk factor (3 points) in the Padua score — patients with active malignancy on chemotherapy or with known metastases should almost always receive VTE prophylaxis.
• A history of VTE (DVT or PE) adds 3 points, making prior VTE a near-automatic indication for prophylaxis in any hospitalized medical patient.
• Immobility is defined as anticipated bed rest for ≥3 days — this single factor (3 points) alone reaches the high-risk threshold when combined with any other factor.
• Always assess BLEEDING RISK before initiating anticoagulant prophylaxis — use a parallel bleeding risk tool (IMPROVE Bleeding Risk Score or ACCP bleeding risk checklist). High VTE risk + high bleeding risk → mechanical prophylaxis only until bleeding risk resolves.
• The Padua score was validated in the pre-DOAC era — oral DOACs are not yet standard for inpatient VTE prophylaxis in medical patients but are being studied.
• Renal impairment (CrCl <30 mL/min) requires dose reduction of LMWH (enoxaparin 20 mg SC daily instead of 40 mg).
• Recent trauma or surgery in the past 30 days adds 2 points, reflecting residual hypercoagulability from tissue injury.
• Combined Padua + IMPROVE Bleeding Risk Score approach is recommended by CHEST guidelines for a balanced thrombosis vs. bleeding risk assessment.

Next steps

Score ≥4 (High Risk — VTE Rate 11% without prophylaxis): Initiate pharmacological thromboprophylaxis: LMWH preferred (e.g., enoxaparin 40 mg SC daily; reduce to 20 mg SC daily if CrCl <30 mL/min). UFH 5,000 units SC every 8–12 hours as alternative. Fondaparinux 2.5 mg SC daily as alternative for HIT history. Continue for the duration of hospitalization and consider extended prophylaxis (28–45 days post-discharge) for highest-risk patients (cancer, immobility). Add mechanical prophylaxis (compression stockings, IPC) as adjunct. Score <4 (Low Risk — VTE Rate 0.3%): Pharmacological prophylaxis not routinely indicated based on VTE risk alone. Early mobilization, adequate hydration. Mechanical prophylaxis (compression stockings) can be used. Reassess daily for change in risk status.

Evidence

Barbar S et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450-2457. PMID:20738765. Derivation cohort: 1,180 medical inpatients. Validation cohort: separate prospective study. High-risk (score ≥4) without prophylaxis: 90-day VTE rate 11.0%. Low-risk (score <4): 90-day VTE rate 0.3%. CHEST 2012 guidelines incorporated Padua score as recommended VTE risk stratification tool for medical inpatients.

References

1. Barbar S et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450-2457. — link
2. Kahn SR et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e195S-226S. — link
3. Konstantinides SV et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543-603. — link